Skip to main content
. Author manuscript; available in PMC: 2022 Apr 15.
Published in final edited form as: Antiviral Res. 2021 Aug 4;194:105158. doi: 10.1016/j.antiviral.2021.105158

Table 1.

PA substitutions conferring >3-fold reduced susceptibility to baloxavir compared to wild-type viruses.a.

NI No information.

a

or to median (Takashita et al., 2019c).

b

Corresponds to F36V in influenza B PA.

c

96%: 4% variant: WT.

d

Corresponds to E120D in influenza B PA.